5PSQ-038 Safety of cyclin dependent kinase inhibitors in the treatment of breast cancer with positive hormonal receptors and negative human epidermal growth factor receptor 2

L Rendón De Lope, C Castillo-Martin, MD Alvarado Fernández, R Castillejo García, A Martinez Suarez, J Cordero Ramos
2020 Section 5: Patient Safety and Quality assurance   unpublished
doi:10.1136/ejhpharm-2020-eahpconf.355 fatcat:a5dsny53bvdwno3hyci7umqfhe